Greg Laub

Real-world French study finds broad benefit, solid comfort, high use

Despite approval of tirzepatide in OSA, a lack of protocols slows uptake in sleep medicine

'This isn't an issue of willpower or anything else,' says Spencer Nadolsky, DO

Leigh Turner, PhD, explains the evidence gap and how athletes fuel risky markets

James Lawler, MD, MPH, says a coordinating office for U.S. biodefense strategy is a necessity

Experts explore prospects for post-neoadjuvant use in early disease as well as metastatic setting

Study from China not ready for prime time

Experts discuss biomarker-driven strategies and adaptive trial design

On ASCO 2025: 'every room I walk into here, I see something new and something exciting'

'We need more inclusive enrollment in the trials that guide approvals,' says Zunairah Shah, MD

Kevin Kalinsky, MD, discusses the standout trials

Removing carboplatin may preserve outcomes while reducing side effects

Sara Tolaney, MD, MPH, discusses the results of the DESTINY-Breast09 trial

'We don't want to see women die because they're denied lifesaving care,' says former CMS chief

Hope Rugo, MD, leads a discussion with William Gradishar, MD, and Laura Huppert, MD

Former CMS administrator reflects on her challenges, wins, and advice for her successor

DESTINY-Breast09 trial may shift first-line standard but raises long-term toxicity questions

CRS and ICANS rates comparable regardless of autoimmune disease history

Hope Rugo, MD, leads a discussion with William Gradishar, MD, and Laura Huppert, MD

New Focus on Hypercortisolism, Cardiovascular Risks in Diabetes